Molecular pathways in pancreatic carcinogenesis

Journal of Surgical Oncology

Volumn 107, Issue 1, 2013, Pages 8-14

  MacGregor Das, Anne M ^a   Iacobuzio Donahue, Christine A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

cystic neoplasm; GNAS; pancreatic cancer; RNF43

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; MIXED LINEAGE LEUKEMIA PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; RING FINGER PROTEIN; SMAD4 PROTEIN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CHROMATIN STRUCTURE; DNA ISOLATION; EXOME; GENE DELETION; GENE DOSAGE; GENE MUTATION; GENE SEQUENCE; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MUCINOUS CYSTIC NEOPLASM; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS CANCER; PRIORITY JOURNAL; SOMATIC MUTATION; UBIQUITINATION; UNTRANSLATED REGION; VON HIPPEL LINDAU DISEASE;

CARCINOMA IN SITU; CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION, NEOPLASTIC; CYSTADENOCARCINOMA, MUCINOUS; DISEASE PROGRESSION; DNA-BINDING PROTEINS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; MUTATION; ONCOGENE PROTEINS; PANCREATIC NEOPLASMS;

EID: 84871312925     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23213     Document Type: Article

References (62)

1. Siegel R, Naishadham D, Jemal A:, Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
2. Bardeesy N, DePinho RA:, Pancreatic cancer biology and genetics. Nat Rev Cancer 2002; 2: 897-909.
3. Maitra A, Hruban RH:, Pancreatic cancer. Annu Rev Pathol 2008; 3: 157-188.
4. Hruban RH, Adsay NV, Albores-Saavedra J, et al.: Pancreatic intraepithelial neoplasia: A new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001; 25: 579-586.
5. Matthaei H, Schulick RD, Hruban RH, et al.: Cystic precursors to invasive pancreatic cancer. Nat Rev Gastroenterol Hepatol 2011; 8: 141-150.
6. Hruban RH, Takaori K, Klimstra DS, et al.: An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 2004; 28: 977-987.
7. Gaujoux S, Brennan MF, Gonen M, et al.: Cystic lesions of the pancreas: Changes in the presentation and management of 1,424 patients at a single institution over a 15-year time period. J Am Coll Surg 2011; 212: 590-600; discussion 600-603.
8. Maitra A, Fukushima N, Takaori K, et al.: Precursors to invasive pancreatic cancer. Adv Anat Pathol 2005; 12: 81-91.
9. van Heek NT, Meeker AK, Kern SE, et al.: Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 2002; 161: 1541-1547.
10. Kanda M, Matthaei H, Wu J, et al.: Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 2012; 142: 730-733.
11. Caldas C, Kern SE:, K-ras mutation and pancreatic adenocarcinoma. Int J Pancreatol 1995; 18: 1-6.
12. Schubbert S, Shannon K, Bollag G:, Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308.
13. Calhoun ES, Jones JB, Ashfaq R, et al.: BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: Potential therapeutic targets. Am J Pathol 2003; 163: 1255-1260.
14. Schutte M, Hruban RH, Geradts J, et al.: Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997; 57: 3126-3130.
15. Caldas C, Hahn SA, da Costa LT:, Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994; 8: 27-32.
16. Larsson LG:, Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence. Semin Cancer Biol 2011; 21: 367-376.
17. Rozenblum E, Schutte M, Goggins M, et al.: Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57: 1731-1734.
18. Kim WY, Sharpless NE:, The regulation of INK4/ARF in cancer and aging. Cell 2006; 127: 265-275.
19. DiGiuseppe JA:, Redston MS, Yeo CJ, et al.: p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995; 147: 884-888.
20. Jones S, Zhang X, Parsons DW, et al.: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806.
21. Redston MS, Caldas C, Seymour AB, et al.: p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994; 54: 3025-3033.
22. Vogelstein B, Kinzler KW:, Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
23. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al.: Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000; 60: 2002-2006.
24. Hahn SA, Schutte M, Hoque AT, et al.: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-353.
25. Siegel PM, Massague J:, Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 2003; 3: 807-821.
26. Dai JL, Bansal RK, Kern SE:, G1 cell cycle arrest and apoptosis induction by nuclear Smad4/Dpc4: Phenotypes reversed by a tumorigenic mutation. Proc Natl Acad Sci USA 1999; 96: 1427-1432.
27. Tascilar M, Skinner HG, Rosty C, et al.: The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001; 7: 4115-4121.
28. Iacobuzio-Donahue CA, Fu B, Yachida S, et al.: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009; 27: 1806-1813.
29. Goggins M, Shekher M, Turnacioglu K, et al.: Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998; 58: 5329-5332.
30. Wood LD, Parsons DW, Jones S, et al.: The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113.
31. Jones S, Wang TL, Shih Ie M, et al.: Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330: 228-231.
32. Jones S, Li M, Parsons DW, et al.: Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat 2012; 33: 100-103.
33. Shain AH, Giacomini CP, Matsukuma K, et al.: Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci USA 2012; 109: E252-E259.
34. Wang X, Nagl NG, Wilsker D, et al.: Two related ARID family proteins are alternative subunits of human SWI/SNF complexes. Biochem J 2004; 383: 319-325.
35. Ruault M, Brun ME, Ventura M, et al.: MLL3, a new human member of the TRX/MLL gene family, maps to 7q36, a chromosome region frequently deleted in myeloid leukaemia. Gene 2002; 284: 73-81.
36. Sjoblom T, Jones S, Wood LD, et al.: The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314: 268-274.
37. Balakrishnan A, Bleeker FE, Lamba S, et al.: Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res 2007; 67: 3545-3550.
38. Mann KM, Ward JM, Yew CC, et al.: Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci USA 2012; 109: 5934-5941.
39. Sessa F, Solcia E, Capella C, et al.: Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: An investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Arch 1994; 425: 357-367.
40. Hong SM, Park JY, Hruban RH, et al.: Molecular signatures of pancreatic cancer. Arch Pathol Lab Med 2011; 135: 716-727.
41. Yamaguchi H, Kuboki Y, Hatori T, et al.: Somatic mutations in PIK3CA and activation of AKT in intraductal tubulopapillary neoplasms of the pancreas. Am J Surg Pathol 2011; 35: 1812-1817.
42. Schonleben F, Qiu W, Bruckman KC, et al.: BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett 2007; 249: 242-248.
43. Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, et al.: Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: Comparison with conventional ductal adenocarcinomas. Am J Pathol 2000; 157: 755-761.
44. Sahin F, Maitra A, Argani P, et al.: Loss of Stk11/Lkb1 expression in pancreatic and biliary neoplasms. Mod Pathol 2003; 16: 686-691.
45. Jansen M, Ten Klooster JP, Offerhaus GJ, et al.: LKB1 and AMPK family signaling: The intimate link between cell polarity and energy metabolism. Physiol Rev 2009; 89: 777-798.
46. Su GH, Hruban RH, Bansal RK, et al.: Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999; 154: 1835-1840.
47. Lim W, Olschwang S, Keller JJ, et al.: Relative frequency and morphology of cancers in STK11 mutation carriers. Gastroenterology 2004; 126: 1788-1794.
48. Giardiello FM, Brensinger JD, Tersmette AC, et al.: Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119: 1447-1453.
49. Thompson LD, Becker RC, Przygodzki RM, et al.: Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-grade malignant potential) of the pancreas: A clinicopathologic study of 130 cases. Am J Surg Pathol 1999; 23: 1-16.
50. Waters JA, Schmidt CM:, Intraductal papillary mucinous neoplasm-When to resect ? Adv Surg 2008; 42: 87-108.
51. Basturk O, Coban I, Adsay NV:, Pancreatic cysts: Pathologic classification, differential diagnosis, and clinical implications. Arch Pathol Lab Med 2009; 133: 423-438.
52. Furukawa T, Kuboki Y, Tanji E, et al.: Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 2011; 1: 161.
53. Wu J, Jiao Y, Dal Molin M, et al.: Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci USA 2011; 108: 21188-21193.
54. Sugiura T, Yamaguchi A, Miyamoto K:, A cancer-associated RING finger protein, RNF43, is a ubiquitin ligase that interacts with a nuclear protein, HAP95. Exp Cell Res 2008; 314: 1519-1528.
55. Hammel PR, Vilgrain V, Terris B, et al.: Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology 2000; 119: 1087-1095.
56. 2 sensing and cancer. Nat Rev Cancer 2008; 8: 865-873.
57. Verheyen EM, Gottardi CJ:, Regulation of Wnt/beta-catenin signaling by protein kinases. Dev Dyn 2010; 239: 34-44.
58. Morin PJ, Sparks AB, Korinek V, et al.: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997; 275: 1787-1790.
59. Garcea G, Ong SL, Rajesh A, et al.: Cystic lesions of the pancreas. A diagnostic and management dilemma. Pancreatology 2008; 8: 236-251.
60. Tanaka M:, Controversies in the management of pancreatic IPMN. Nat Rev Gastroenterol Hepatol 2011; 8: 56-60.
61. Allen PJ, Brennan MF:, The management of cystic lesions of the pancreas. Adv Surg 2007; 41: 211-228.
62. Yachida S, Jones S, Bozic I, et al.: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467: 1114-1117.